A Minimally-invasive Blood-derived Biomarker of Oligodendrocyte Cell-loss in Multiple Sclerosis

A Minimally-invasive Blood-derived Biomarker of Oligodendrocyte Cell-loss in Multiple Sclerosis

Multiple sclerosis (MS) is a neurodegenerative disease of the central nervous system (CNS). Minimally invasive biomarkers of MS are required for disease diagnosis and treatment. Differentially methylated circulating-free DNA (cfDNA) is a useful biomarker for disease diagnosis and prognosis, and may...

Full description

Bibliographic Details
Main Authors:	John A. Olsen, Lauren A. Kenna, Regine C. Tipon, Michael G. Spelios, Mark M. Stecker, Eitan M. Akirav
Format:	Article
Language:	English
Published:	Elsevier 2016-08-01
Series:	EBioMedicine
Subjects:	Relapsing-remitting multiple sclerosis Oligodendrocyte Cuprizone Human patients Circulating free DNA Biomarker discovery
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352396416302882

Similar Items

Astaxanthin Reduces Demyelination and Oligodendrocytes Death in A Rat Model of Multiple Sclerosis
by: Alireza Lotfi, et al.
Published: (2021-01-01)

The AMPK activator metformin improves recovery from demyelination by shifting oligodendrocyte bioenergetics and accelerating OPC differentiation
by: Mohanlall Narine, et al.
Published: (2023-10-01)

Oligodendrocyte death and myelin loss in the cuprizone model: an updated overview of the intrinsic and extrinsic causes of cuprizone demyelination
by: Martin Zirngibl, et al.
Published: (2022-05-01)

Effect of swimming on oligodendrocytic cells and myelin tissue in corpus callosum of rat model of MS induced by Cuprizone
by: Ebrahim Bagheri, et al.
Published: (2021-02-01)

Effect of Rituximab Compared with Natalizumab and Fingolimod in Patients with Relapsing–Remitting Multiple Sclerosis: A Cohort Study
by: Martha Rocio Hernández-Preciado, et al.
Published: (2022-06-01)

CDP-choline to promote remyelination in multiple sclerosis: the need for a clinical trial
by: Viktoria Gudi, et al.
Published: (2023-01-01)

Deciphering the Genetic Crosstalk between Microglia and Oligodendrocyte Precursor Cells during Demyelination and Remyelination Using Transcriptomic Data
by: Jennifer Enrich-Bengoa, et al.
Published: (2022-11-01)

Comparing the Efficacy of Monthly Cyclophosphamide as Monotherapy versus Daily Fingolimod in Relapsing Remitting and Secondary Progressive Multiple Sclerosis
by: Vahid Shaygannezhad, et al.
Published: (2017-08-01)

Rapid Progression of Low-Grade Cervical Dysplasia into Invasive Cancer during Natalizumab Treatment for Relapsing Remitting Multiple Sclerosis
by: King Man Wan, et al.
Published: (2019-01-01)

How to Use the Cuprizone Model to Study De- and Remyelination
by: Markus Kipp
Published: (2024-01-01)

Delayed Demyelination and Impaired Remyelination in Aged Mice in the Cuprizone Model
by: Stefan Gingele, et al.
Published: (2020-04-01)

Gut microbiota in forty cases of egyptian relapsing remitting multiple sclerosis
by: Sherein G. Elgendy, et al.
Published: (2021-10-01)

Vitamin D intoxication in a patient with relapsing-remitting multiple sclerosis – case report
by: Ioana Cociasu, et al.
Published: (2015-09-01)

Circulating miRNAs as Potential Biomarkers Distinguishing Relapsing–Remitting from Secondary Progressive Multiple Sclerosis. A Review
by: Sylwia Pietrasik, et al.
Published: (2021-11-01)

Exploring the Relationship between Antioxidant Enzymes, Oxidative Stress Markers, and Clinical Profile in Relapsing–Remitting Multiple Sclerosis
by: Anna Bizoń, et al.
Published: (2023-08-01)

Cognitive profile of patients with relapsing remitting multiple sclerosis
by: VIVIAN M. ANDRADE, et al.
Published: (1999-09-01)

Development and Validation of Fear of Relapse Scale for Relapsing-Remitting Multiple Sclerosis: Understanding Stressors in Patients
by: Ali Khatibi, et al.
Published: (2020-03-01)

Ferulic Acid Ameliorates Cell Injuries, Cognitive and Motor Impairments in Cuprizone-Induced Demyelination Model of Multiple Sclerosis
by: Mojtaba Ghobadi, et al.
Published: (2022-11-01)

Regenerative Effects of CDP-Choline: A Dose-Dependent Study in the Toxic Cuprizone Model of De- and Remyelination
by: Viktoria Gudi, et al.
Published: (2021-11-01)

Experience of Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients
by: Özlem Taşkapılıoğlu, et al.
Published: (2012-03-01)

Experience of Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients
by: Özlem Taşkapılıoğlu, et al.
Published: (2012-03-01)

Comparison of efficacy and safety of oral agents for the treatment of relapsing–remitting multiple sclerosis
by: Guarnera C, et al.
Published: (2017-07-01)

Abcd1 deficiency accelerates cuprizone-induced oligodendrocyte loss and axonopathy in a demyelinating mouse model of X-linked adrenoleukodystrophy
by: Ksenija Martinović, et al.
Published: (2023-06-01)

Differential Role of p53 in Oligodendrocyte Survival in Response to Various Stresses: Experimental Autoimmune Encephalomyelitis, Cuprizone Intoxication or White Matter Stroke
by: Fucheng Luo, et al.
Published: (2021-11-01)

Comparing power and activity of lower body muscles in two types of multiple sclerosis patients and healthy individuals
by: Talebi V, et al.
Published: (2020-05-01)

IL-18 PROMOTER POLYMORPHISM AND IL-18 SERUM LEVELS IN ASSOCIATION WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS
by: Boncho Grigorov, et al.
Published: (2020-12-01)

Intrinsic functional plasticity of the thalamocortical system in minimally disabled patients with relapsing-remitting multiple sclerosis
by: Fuqing eZhou, et al.
Published: (2016-01-01)

Long-Term Disability Outcomes in Relapsing–Remitting Multiple Sclerosis Patients: Impact of Clinical and Demographic Factors on Disease Progression
by: Laura Barcutean, et al.
Published: (2024-03-01)

Clinical markers for unfavorable course of multiple sclerosis
by: Mariya S. Matrosova, et al.
Published: (2023-09-01)

Postural Control in Relapsing-Remitting Multiple Sclerosis
by: Flavia Salvaterra Cusin, et al.
Published: (2022-10-01)

Subcutaneous Ofatumumab in Patients with Relapsing-remitting Multiple Sclerosis
by: Halil Önder
Published: (2019-06-01)

Mechanisms of remyelination: recent insight from experimental models
by: Tanaka Tatsuhide, et al.
Published: (2014-08-01)

On the Move: Correlation of Impaired Mobility with Spatial Navigation Ability in Persons with Multiple Sclerosis
by: Alexis N. Chargo, et al.
Published: (2024-03-01)

Investigation of oxidative stress in relapse and remission periods of patients with relapsing-Remitting multiple sclerosis
by: Samet Oncel, et al.
Published: (2021-01-01)

Comparison of Expression Levels of miR-29b-3p and miR-326 in T Helper-1 and T Helper-17 Cells Isolated from Responsive and Non-responsive Relapsing-remitting Multiple Sclerosis Patients Treated with Interferon-beta
by: Leila Karimi, et al.
Published: (2020-08-01)

Recent Progress in the Identification of Early Transition Biomarkers from Relapsing-Remitting to Progressive Multiple Sclerosis
by: Smaranda Maier, et al.
Published: (2023-02-01)

Expansion of Neutrophils and Classical and Nonclassical Monocytes as a Hallmark in Relapsing-Remitting Multiple Sclerosis
by: David Haschka, et al.
Published: (2020-04-01)

Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia
by: Mansour A. Alharbi, et al.
Published: (2023-05-01)

Highly Active Relapsing-Remitting Multiple Sclerosis with Neurofibromatosis Type 1: Radiological Aspects and Therapeutic Challenges – Case Report
by: Marios Lemonaris, et al.
Published: (2024-01-01)

Oligodendrocyte Development and Regenerative Therapeutics in Multiple Sclerosis
by: Nadjet Gacem, et al.
Published: (2021-04-01)